<DOC>
	<DOCNO>NCT00636311</DOCNO>
	<brief_summary>The purpose study evaluate addition Bortezomib ( Velcade ) IGEV combination ( Ifosfamide , Gemcitabine Vinorelbine ) patient relapsed/refractory Hodgkin 's lymphoma increase rate complete remission ( PET negativity ) transplantation .</brief_summary>
	<brief_title>A Phase II Study IGEV +/- Bortezomib Before Hign Dose Consolidation Relapsed/Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Diagnosis Hodgkin 's lymphoma fail relapse firstline chemotherapy ( MOPP/AVBD , MOPP/EBV/CAD analogs consider one line ) Age &gt; 18 &lt; 65 year Signed informed consent If female , patient either postmenopausal surgically sterilize willing use acceptable method birth control If male , patient agrees use acceptable barrier method contraception ECOG performance status &lt; 2 Platelet count &gt; 100.000/mmc Hemoglobin &gt; 7.5 g/dL Absolute neutrophil count ( ANC ) &gt; 1.500/mmc Serum calcium &lt; 3.5 mmol/L ( &lt; 14 mg/dL ) AST/ALT : &lt; 2.5 x ULN Total bilirubin : &lt; 1.5 x ULN Previous treatment velcade Nitrosoureas within 6 week chemotherapy within 3 week enrollment Immunotherapy antibody therapy within 4 week enrollment Experimental drug medical device within 4 week start treatment Major surgery within 4 week enrollment History allergic reaction attributable compound contain boron mannitol drug IGEV regimen Peripheral neuropathy NCI CTCAE Grade 2 high Myocardial infarction within 6 month enrollment NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance include diabetes mellitus Need therapy concomitant CYP 3A4 inhibitor inducer HIVpositive , know Hepatitis B surface antigenpositive active hepatitis C infection , know Active systemic infection require treatment If female , pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hodgkin disease</keyword>
	<keyword>Salvage therapy</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Transplantation</keyword>
</DOC>